The global NASH (Non-alcoholic Steatohepatitis) Biomarkers market was valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025.
This report focuses on NASH (Non-alcoholic Steatohepatitis) Biomarkers volume and value at global level, regional level and company level. From a global perspective, this report represents overall NASH (Non-alcoholic Steatohepatitis) Biomarkers market size by analyzing historical data and future prospect.
Regionally, this report categorizes the production, apparent consumption, export and import of NASH (Non-alcoholic Steatohepatitis) Biomarkers in North America, Europe, China, Japan, Southeast Asia and India.
For each manufacturer covered, this report analyzes their NASH (Non-alcoholic Steatohepatitis) Biomarkers manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.

The following manufacturers are covered:
GENFIT SA
Gilead Sciences, Inc. (GILD)
AstraZeneca
Novartis AG
Bristol-Myers Squibb Company
Allergan Plc
Novo Nordisk A/S
Boehringer Ingelheim
Pfizer Inc

Segment by Regions
North America
Europe
China
Japan
Southeast Asia
India

Segment by Type
Serum biomarkers
Hepatic fibrosis biomarkers
Apoptosis biomarkers
Oxidative stress biomarkers
Others

Segment by Application
Pharma & CRO Industry
Hospitals
Diagnostic Labs
Academic Research Institutes